NCT05054322 (FLOT) is a Phase 2, PHASE3 clinical trial of Fluticasone Propionate in Covid19, sponsored by University of Medicine and Pharmacy at Ho Chi Minh City.

Who is sponsoring NCT05054322?

NCT05054322 is sponsored by University of Medicine and Pharmacy at Ho Chi Minh City.

What drugs are being tested in NCT05054322?

Interventions in NCT05054322: Fluticasone Propionate.

Is NCT05054322 still recruiting?

NCT05054322 is currently status unknown. Last updated 23 September 2021.

Last reviewed 2021-09-23 · How we verify

NCT05054322: FLOT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FLuticasone in cOvid Treatment (FLOT)

Status unknown Phase 2, PHASE3 Last updated 23 September 2021

What this trial tests

Phase 2, PHASE3 trial testing Fluticasone Propionate in Covid19 in 500 participants. Status unknown.

Timeline

22 September 2021

Primary endpoint
31 January 2022

30 August 2022

Quick facts

Lead sponsor	University of Medicine and Pharmacy at Ho Chi Minh City
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	500
Start date	22 September 2021
Primary completion	31 January 2022
Estimated completion	30 August 2022
Sites	1 location across Vietnam

Drugs / interventions tested

Fluticasone Propionate (FLUTICASONE PROPIONATE) — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

University of Medicine and Pharmacy at Ho Chi Minh City

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter, open-label, randomized controlled trial to evaluate the efficacy of fluticasone propionate (metered dose inhaler - MDI) added to standard care at early stage of COVID-19 in reducing the incidence of adverse outcomes (any of those following: oxygen therapy, systemic corticosteroids, hospitalization, mechanical ventilation, and mortality) in symptomatic patients either from 18 to 49 years of age with risk factors or older than 50 years.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Inhaled corticosteroids for the treatment of COVID-19.
Griesel M, Wagner C, Mikolajewska A, Stegemann M, et al · · 2022 · cited 52× · PMID 35262185 · DOI 10.1002/14651858.cd015125
Inhaled corticosteroids for the treatment of COVID-19.
Bafadhel M, Faner R, Taillé C, Russell REK, et al · · 2022 · cited 12× · PMID 36450371 · DOI 10.1183/16000617.0099-2022

Verify or expand the search:

Other trials of Fluticasone Propionate

Trials testing the same drug.

NCT05535738 — Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation · Phase 2, PHASE3 · recruiting
NCT05314621 — A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With · Phase 4 · completed
NCT05444543 — Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis) · Phase 4 · completed
NCT04601324 — Allergic Rhinitis Combination Pharmacotherapy Efficacy Study · Phase 4 · withdrawn
NCT04242368 — Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis · Phase 2, PHASE3 · withdrawn

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other University of Medicine and Pharmacy at Ho Chi Minh City trials

Trials by the same sponsor.

NCT07530042 — Efficacy of Electroacupuncture Combined With Auricular Acupressure for Chronic Low Back Pain. · NA · not yet recruiting
NCT07537439 — Evaluation of the Adjunctive Effects of Moxibustion in the Treatment of Cold-Syndrome Allergic Rhinitis · NA · not yet recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT07520071 — "Xuong Tan Lac Than" Exercise for Range of Motion and Muscle Endurance · NA · recruiting
NCT07487181 — A Survey of Traditional Medicine Pattern Identification in Patients With Erectile Dysfunction · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05054322 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Medicine and Pharmacy at Ho Chi Minh City
Last refreshed: 23 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05054322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing